Journal of Clinical Oncology
Articles in this Issue
Analysing the impact of size of NGS panel in defining first line therapeutic strategies in NSCLC.
3070 Background: NCCN recommends the analysis of 8 genes (EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, ERBB2, and NTRK1/2/3) for NSCLC patients to identify effi...
Efficacy and safety results of TQB2930, a HER2-targeted bispecific antibody combined with chemotherapy in patients with HER2-positive breast cancer (BC) previously treated with ≥2 line treatments: Results from a phase 1b/2 study.
1033 Background: TQB2930 is a HER2-targeted bispecific antibody designed to bind two distinct HER2 epitopes: the extracellular domain 4 (ECD4), and the ex...
Integrative clinical, genomic, and transcriptomic characterization of circulating KIM-1 in metastatic RCC.
4546 Background: Kidney injury molecule-1 (KIM-1) is a transmembrane protein that is overexpressed in renal cell carcinoma (RCC) and correlated with clini...
Lymphovascular invasion as a prognostic factor in pT2 urothelial carcinoma.
e16582 Background: Although neoadjuvant therapy is the standard of care for muscle-invasive bladder cancer, up to 40% of patients still undergo cystectomy...
Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: An update on SHATA-001 study.
4100 Background: Although sorafenib plus transcatheter arterial chemoembolization (SoraTACE) has been widely applied for advanced hepatocellular carcinoma...
Neoadjuvant cetuximab plus tislelizumab combined with chemotherapy in pMMR RAS/BRAF wild-type (wt) locally advanced rectal cancer (LARC): A prospective, multicenter, phase II study.
TPS3640 Background: For patients (pts) with locally advanced rectal cancer (LARC), chemoradiotherapy followed by total mesorectal excisionis is recommende...
Efficacy of targeted therapy versus immunotherapy in metastatic colorectal cancer: A systematic review and meta-analysis.
e15593 Background: The management of metastatic colorectal cancer (mCRC) has evolved with the advent of targeted therapies and immunotherapy. While target...
Impact of alcohol and drug dependence among hospitalized patients with cancers of the lip, oral cavity and pharynx.
e18032 Background: Alcohol and drug dependence is one of the most often seen addiction in the US and we are unaware of the impact of those addictions in t...
The utility of genomic profiling in prostate cancer: Insights from a phase I setting.
e17062 Background: Prostate cancer, one of the most frequent cancers among men, has increasingly benefited from precision oncology during the last decade,...
PYNNACLE phase 2 clinical trial of rezatapopt in patients with advanced solid tumors harboring a <i>TP53</i> Y220C mutation.
TPS11581 Background: TP53, encoding p53 protein, is one of the most frequently mutated genes across all cancers, with TP53 mutations found in...
Prognostic validation of six androgen production, uptake, and conversion genes (APUC-6) in the CHAARTED prostate cancer trial.
5089 Background: Metastatic prostate cancer (mPC), whether synchronous or metachronous, remains incurable. Persistent androgen receptor (AR) activation pr...
Monitoring populations of tumor-macrophage fusion cells in blood prognosticates PFS and OS in pan-metastatic cancers over 2 years.
3058 Background: Tumor associated macrophages are known to fuse with cancer cells in the blood through a dysfunctional CD47 phagocytic immune pathway resu...
RECAST (Re-Evaluating Conditions for Active Surveillance Suitability as Treatment) for DCIS: Clinical trial in progress.
TPS624 Background: Ductal Carcinoma In Situ (DCIS) is a condition where cancerous cells are confined to the breast ducts. The standard of care is surgery,...
Chemotherapy-free survival in HR-positive HER2-negative breast cancer: CDK4/6 inhibitors combination vs. endocrine monotherapy.
e13050 Background: Treatment of hormone receptor (HR)-positive HER2-negative advanced breast cancer (ABC) with CDK4/6 inhibitors (CDK4/6i) significantly e...
Race-associated clinicogenomic correlates of outcomes to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer (NSCLC).
8567 Background: PD-L1 low and STK11 mutations are associated with immune checkpoint inhibitor (ICI) resistance in non-small cell lung cancer (NSCLC). It...
Impacting quality of life and pancreatic cancer survivorship through a telehealth intervention.
TPS1663 Background: Pancreatic cancer patients experience significant debilitating symptoms as a direct or indirect result of disease, treatment, and co-m...
A phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/refractory non-Hodgkin lymphoma.
7012 Background: Prognosis of relapsed/refractory (R/R) non-Hodgkin Lymphoma (NHL) which has progressed on standard therap...
Impact of tumor lysis syndrome on clinical outcomes and healthcare burden in chimeric antigen receptor T-cell therapy patients: Key insights from United States population data.
e19000 Background: Tumor lysis syndrome (TLS) is a known complication of hematologic malignancy treatments, often leading to fatal arrhythmias, acute kidn...
Alliance A221805: Duloxetine to prevent oxaliplatin-induced chemotherapy-induced peripheral neuropathy (CIPN)—A randomized, double-blind, placebo-controlled phase II study.
12010 Background: Standard-of-care chemotherapy treatment regimens for colorectal cancer (CRC) include oxaliplatin, a drug known for causing CIPN. CIPN is...
SARC-Digital: interim analysis of the effectiveness of digital health interventions on the quality of life of metastatic sarcoma patients.
e23018 Background: Patients with advanced or metastatic sarcoma face several challenges regarding their quality of life.SARC-Digital prospective randomize...
Ultra-sensitive detection of hepatocellular carcinoma (HCC) with methylation signal enrichment of ctDNA and hepatitis B virus (HBV).
4136 Background: Aberrant methylation patterns in cell-free DNA (cfDNA) have been identified as effective biomarkers for HCC early detection, with circula...
Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling.
11155 Background: Broad genomic profiling (BGP) is increasingly performed for patients with advanced non-small cell lung cancer (aNSCLC) to inform the use...
External validation of a pathology-based multimodal artificial intelligence biomarker for predicting prostate cancer outcomes after prostatectomy.
5106 Background: Radical prostatectomy (RP) improves survival and delays metastasis in localized prostate cancer (PCa) patients (pts), yet 20-40% of men e...
Predictors of preventive breast cancer screening: Findings from a national dataset.
e22500 Background: Breast cancer is a major health concern and is the most common cancer in women according to the American Cancer Society with 1 in 3 wom...
TAPS chemistry: A novel, ultrasensitive pan-CNS cancer liquid biopsy assay.
e14034 Background: The gold standard of diagnosis for central nervous system (CNS) malignancy is biopsy of the tumor, an invasive procedure that, at times...